It is noteworthy that the effectiveness of this cotreatment in both ASS1− and ASS1+ pancreatic cancer cells is unique to the arginine depletion imposed by PEG-BCT-100 but may not apply to other arginine-depleting agents. The gene discussed is ASS1; the disease is familial pancreatic carcinoma.